1-2 of 2
Deborah S Ricci
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study

Bertrand Coiffier, MD, Weimin Li, Erin D Henitz, BS, J. D. Karkera, PhD, Reyna Favis, PhD, Dana Gaffney, MS, Alice Shapiro, MS, Panteli Theocharous, BSc (hons), MSc, PhD, Yusri A Elsayed, MD, PhD, Helgi van de Velde, MD, PhD, Evgenii A Osmanov, MD, PhD, Xiaonan Hong, MD, Adriana Scheliga, MD, Fritz C. Offner, MD, PhD, Simon Rule, Adriana C Teixeira, MD, Jan Walewski, MD, PhD, Sven de Vos, MD, PhD, Michael Crump, MD, FRCPC, Ofer Shpilberg, MD, MPH, Pier Luigi Zinzani, MD, PhD, Andrew Z Cakana, MD, FRCPath, Dixie-Lee Esseltine, MD, FRCPC, George Mulligan, PhD, Deborah S Ricci, PhD
Journal: Blood
Blood (2011) 118 (21): 265.
https://doi.org/10.1182/blood.V118.21.265.265
Published: 2011
Journal Articles

Pharmacogenomic (PGx) Analysis of Bortezomib-Associated Peripheral Neuropathy in the Phase 3 VISTA Trial of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone in Multiple Myeloma.

Deborah S Ricci, Reyna Favis, Yu Sun, Helgi van de Velde, Erin Broderick, Michael Meyers, Jean-Luc Harousseau, Hervé Avet-Loiseau, Paul G Richardson, Jesús F San Miguel
Journal: Blood
Blood (2009) 114 (22): 3875.
https://doi.org/10.1182/blood.V114.22.3875.3875
Published: 2009